Cargando…

Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease

BACKGROUND AND PURPOSE: The goal of this study was to estimate the efficacy and safety of the rivastigmine transdermal patch in patients with probable Alzheimer's disease (AD) who cannot tolerate or do not respond to oral cholinesterase inhibitors (ChEIs). METHODS: A 24-week, prospective, open-...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Hyun Jeong, Lee, Jeong Ju, Park, Sun A., Park, Hyun Young, Kim, Jeong Eun, Shim, Young Soo, Shim, Dong-Seok, Kim, Eun-Joo, Yoon, Soo Jin, Choi, Seong Hye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neurological Association 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212599/
https://www.ncbi.nlm.nih.gov/pubmed/22087207
http://dx.doi.org/10.3988/jcn.2011.7.3.137
_version_ 1782215997209444352
author Han, Hyun Jeong
Lee, Jeong Ju
Park, Sun A.
Park, Hyun Young
Kim, Jeong Eun
Shim, Young Soo
Shim, Dong-Seok
Kim, Eun-Joo
Yoon, Soo Jin
Choi, Seong Hye
author_facet Han, Hyun Jeong
Lee, Jeong Ju
Park, Sun A.
Park, Hyun Young
Kim, Jeong Eun
Shim, Young Soo
Shim, Dong-Seok
Kim, Eun-Joo
Yoon, Soo Jin
Choi, Seong Hye
author_sort Han, Hyun Jeong
collection PubMed
description BACKGROUND AND PURPOSE: The goal of this study was to estimate the efficacy and safety of the rivastigmine transdermal patch in patients with probable Alzheimer's disease (AD) who cannot tolerate or do not respond to oral cholinesterase inhibitors (ChEIs). METHODS: A 24-week, prospective, open-label, single-arm, multicenter study was conducted from June 2009 to June 2010 in patients with probable AD. The enrolled patients had either a poor response or a decline in global function after treatment with oral ChEIs, or they were not able to tolerate treatment with oral ChEIs due to adverse events such as nausea or vomiting. A poor response was defined as a decrease of at least 2 points on the Korean version of the Mini-Mental State Examination (K-MMSE) within the previous 6 months (the decline in global function was determined by the investigator or caregiver). The efficacy of treatment was assessed using a follow-up Clinical Global Impression of Change (CGIC) assessment and K-MMSE conducted after 24 weeks, and safety was measured by the occurrence of adverse events and patient disposition. RESULTS: In total, 164 patients aged 74.7±7.52 years (mean±SD) and with 5.12±3.64 years of education were included. The study was completed by 70% of the patients (n=116), with 12.2% discontinuing due to adverse events. The most frequently reported adverse events (11%) were skin lesions, such as erythema or itching, followed by gastrointestinal problems (1.2%). Either an improvement or no decline in CGIC scores was reported for 82% of the patients. CONCLUSIONS: The immediate switching of patients from an oral ChEI to the rivastigmine transdermal patch without a washout period was safe and well tolerated by the probable-AD patients in this study.
format Online
Article
Text
id pubmed-3212599
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Korean Neurological Association
record_format MEDLINE/PubMed
spelling pubmed-32125992011-11-15 Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease Han, Hyun Jeong Lee, Jeong Ju Park, Sun A. Park, Hyun Young Kim, Jeong Eun Shim, Young Soo Shim, Dong-Seok Kim, Eun-Joo Yoon, Soo Jin Choi, Seong Hye J Clin Neurol Original Article BACKGROUND AND PURPOSE: The goal of this study was to estimate the efficacy and safety of the rivastigmine transdermal patch in patients with probable Alzheimer's disease (AD) who cannot tolerate or do not respond to oral cholinesterase inhibitors (ChEIs). METHODS: A 24-week, prospective, open-label, single-arm, multicenter study was conducted from June 2009 to June 2010 in patients with probable AD. The enrolled patients had either a poor response or a decline in global function after treatment with oral ChEIs, or they were not able to tolerate treatment with oral ChEIs due to adverse events such as nausea or vomiting. A poor response was defined as a decrease of at least 2 points on the Korean version of the Mini-Mental State Examination (K-MMSE) within the previous 6 months (the decline in global function was determined by the investigator or caregiver). The efficacy of treatment was assessed using a follow-up Clinical Global Impression of Change (CGIC) assessment and K-MMSE conducted after 24 weeks, and safety was measured by the occurrence of adverse events and patient disposition. RESULTS: In total, 164 patients aged 74.7±7.52 years (mean±SD) and with 5.12±3.64 years of education were included. The study was completed by 70% of the patients (n=116), with 12.2% discontinuing due to adverse events. The most frequently reported adverse events (11%) were skin lesions, such as erythema or itching, followed by gastrointestinal problems (1.2%). Either an improvement or no decline in CGIC scores was reported for 82% of the patients. CONCLUSIONS: The immediate switching of patients from an oral ChEI to the rivastigmine transdermal patch without a washout period was safe and well tolerated by the probable-AD patients in this study. Korean Neurological Association 2011-09 2011-09-29 /pmc/articles/PMC3212599/ /pubmed/22087207 http://dx.doi.org/10.3988/jcn.2011.7.3.137 Text en Copyright © 2011 Korean Neurological Association http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Han, Hyun Jeong
Lee, Jeong Ju
Park, Sun A.
Park, Hyun Young
Kim, Jeong Eun
Shim, Young Soo
Shim, Dong-Seok
Kim, Eun-Joo
Yoon, Soo Jin
Choi, Seong Hye
Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
title Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
title_full Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
title_fullStr Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
title_full_unstemmed Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
title_short Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
title_sort efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable alzheimer's disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212599/
https://www.ncbi.nlm.nih.gov/pubmed/22087207
http://dx.doi.org/10.3988/jcn.2011.7.3.137
work_keys_str_mv AT hanhyunjeong efficacyandsafetyofswitchingfromoralcholinesteraseinhibitorstotherivastigminetransdermalpatchinpatientswithprobablealzheimersdisease
AT leejeongju efficacyandsafetyofswitchingfromoralcholinesteraseinhibitorstotherivastigminetransdermalpatchinpatientswithprobablealzheimersdisease
AT parksuna efficacyandsafetyofswitchingfromoralcholinesteraseinhibitorstotherivastigminetransdermalpatchinpatientswithprobablealzheimersdisease
AT parkhyunyoung efficacyandsafetyofswitchingfromoralcholinesteraseinhibitorstotherivastigminetransdermalpatchinpatientswithprobablealzheimersdisease
AT kimjeongeun efficacyandsafetyofswitchingfromoralcholinesteraseinhibitorstotherivastigminetransdermalpatchinpatientswithprobablealzheimersdisease
AT shimyoungsoo efficacyandsafetyofswitchingfromoralcholinesteraseinhibitorstotherivastigminetransdermalpatchinpatientswithprobablealzheimersdisease
AT shimdongseok efficacyandsafetyofswitchingfromoralcholinesteraseinhibitorstotherivastigminetransdermalpatchinpatientswithprobablealzheimersdisease
AT kimeunjoo efficacyandsafetyofswitchingfromoralcholinesteraseinhibitorstotherivastigminetransdermalpatchinpatientswithprobablealzheimersdisease
AT yoonsoojin efficacyandsafetyofswitchingfromoralcholinesteraseinhibitorstotherivastigminetransdermalpatchinpatientswithprobablealzheimersdisease
AT choiseonghye efficacyandsafetyofswitchingfromoralcholinesteraseinhibitorstotherivastigminetransdermalpatchinpatientswithprobablealzheimersdisease